Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Researchers are assessing GC012F (AZD0120) in people with multiple myeloma that came back or keeps growing after treatment. In the first part of this study, researchers will find the best dose of GC012F to use in patients. In the second part of the study, they will assess this dose to treat advanced multiple myeloma.
To learn more about the purpose of this study and to find out who can join, please click here for Substudy 01A or here for Substudy 01C to visit ClinicalTrials.gov for a full clinical trial description.
Researchers in this study want to find the best dose of lurbinectedin to treat cancer in children and adults. They also want to see how well this drug works. The people in this study have Ewing sarcoma or other solid tumors that keep growing after treatment. In addition, their cancers contain a genetic change called a FET fusion.
Researchers want to see if adding autogene cevumeran to nivolumab is better than nivolumab alone to treat urothelial (bladder) cancer. The people in this study have muscle-invasive urothelial cancer (MIUC) that has been removed with surgery.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
I-DXd is a type of drug called an antibody-drug conjugate (ADC). ADCs are made of a monoclonal antibody linked to a drug. The antibody binds to a protein on cancer cells called B7-H3, which plays a role in cancer cell growth. It then releases the anti-cancer drug to kill the cancer cell. By destroying these cells, I-DXd may help slow or stop the growth of your cancer.
Researchers are expanding access to the drug zidesamtinib for people with advanced solid tumors. The people in this study have non-small cell lung cancer (NSCLC) or another solid tumor with a fusion (change) in the ROS1 gene. This fusion can cause cancer cells to multiply and spread.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Chemotherapy for lymphoma can cause side effects, especially in people age 65 and older and those with other health problems. Researchers want to see if adding the immunotherapy drugs glofitamab, polatuzumab, and obinutuzumab to treatment can reduce the amount of chemotherapy needed. The people in this study have diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), or transformed lymphoma. Their cancer has not yet been treated.
